Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
It's a Fact
RipTide Software is no longer associated with Riptide Worldwide. The person I spoke to was unale to state when the association ended...........The moderator should really update the board DD as it is leading to a question of veracity.
It's a Fact
RipTide Software is no longer associated with Riptide Worldwide. The person I spoke to was unale to state when the association ended...........RTWW is developing an odor.
Thanks Crammer
Interesting News
http://www.nasdaq.com/aspx/company-news-story.aspx?storyid=200912011026rttraderusequity_0906
Adventrx Pharma Reports Addl. Pre-Clinical Data For ANX-514
(RTTNews) - Adventrx Pharmaceuticals Inc. (ANX) reported that a new, recently completed preclinical study has affirmed the bioequivalence and comparable toxicity of ANX-514 and Taxotere.
Shin Poong Pharmaceuticals, Adventrx's partner for ANX-514 in South Korea, independently conducted the study and data analysis.
The company said, "We intend next to conduct a separate clinical bioequivalence study of ANX-514 in South Korea and look forward to continuing to work with ADVENTRX toward the possible commercialization of ANX-514 in both the U.S. and South Korea."
Excellant Summary.....tks..
The 505(b)(2) New Drug Application
The 505(b)(2) New Drug Application – A Rapid Approval Route
READ THE LAST PARAGRAPH
The 505(b)(2) regulatory pathway is defined in The Federal Food Drug and Cosmetics Act as an NDA containing investigations of safety and effectiveness that are being relied upon for approval and were not conducted by or for the applicant, and for which the applicant has not obtained a right of reference. These applications differ from the typical NDA (described under Section 505(b)(1) of the Act), in that they allow a sponsor to rely, at least in part, on the FDA’s findings of safety and/or effectiveness for a previously approved drug (the “reference drug”). Section 505(b)(2) was added to the Act in 1984 with the goal of avoiding unnecessary duplication of preclinical and certain human studies. However, the sponsor must still provide any additional preclinical or clinical data necessary to ensure that differences from the reference drug do not compromise safety and effectiveness. The 505(b)(2) NDA also differs from an abbreviated NDA (ANDA; described under Section 505(j) of the Act), which is an application containing information to demonstrate that the proposed product is identical to a previously approved product.
Identity is proven in an ANDA simply through chemistry and bioequivalence data, without the need for preclinical and clinical trials assessing safety and efficacy. In a sense, a 505(b)(2) application can be thought of as a hybrid that contains more data than an ANDA, but less data than an NDA.
The 505(b)(2) New Drug Application – A Rapid Approval Route
READ THE LAST PARAGRAPH
The 505(b)(2) regulatory pathway is defined in The Federal Food Drug and Cosmetics Act as an NDA containing investigations of safety and effectiveness that are being relied upon for approval and were not conducted by or for the applicant, and for which the applicant has not obtained a right of reference. These applications differ from the typical NDA (described under Section 505(b)(1) of the Act), in that they allow a sponsor to rely, at least in part, on the FDA’s findings of safety and/or effectiveness for a previously approved drug (the “reference drug”). Section 505(b)(2) was added to the Act in 1984 with the goal of avoiding unnecessary duplication of preclinical and certain human studies. However, the sponsor must still provide any additional preclinical or clinical data necessary to ensure that differences from the reference drug do not compromise safety and effectiveness. The 505(b)(2) NDA also differs from an abbreviated NDA (ANDA; described under Section 505(j) of the Act), which is an application containing information to demonstrate that the proposed product is identical to a previously approved product.
Identity is proven in an ANDA simply through chemistry and bioequivalence data, without the need for preclinical and clinical trials assessing safety and efficacy. In a sense, a 505(b)(2) application can be thought of as a hybrid that contains more data than an ANDA, but less data than an NDA.
WOW 247K at the ask....
New Support Level??....It would
seem to be forming a new support level. It has been trading between .40-.415 since 9:50.13. This should bode well as we move forward.....
A Thought for All
ANX will be a star performer. If you bought this for a quick flip you're in trouble....If, however, you picked this up with the intention of holding for 3-6-9 months you are in a great position. Sure the pps will dip tomorrow as the those who expected miracles within 24 hrs are disappointed and leave.....this opens a buying opportunity at bargain prices. You will be surprised to see the pps recover and start an orderly advance within a few days to a week. Positive news of any type will merely accelerate the pps with respect to time...Hang in the band is a bit late to the party.
Read someplace that there are 36 employees...not sure where tho.
There's only 3 hours difference...em
Check out Anx....Might be Something...
Keep it on a back burner 4 now
I moved to ANX just in time....There
is too much talk & little concrete results w/EGMI. Money talks BS walks.....
Meant the overall "Stealth Mode" of operation....
Weather here is ....Snow This is NM and it supposed to be the desert...This is the 5th snow (dusting) this year...deepest was 3" which cripples the town as they close up everything & don't even own a plough....Don't know why you'd plough 3" anyway but out here it a gas as most have never driven in the snow
The Silence is Deafening....lol
Could a PR be Coming re CEO/CFO???? em
Thanks Ian....eom
More garbage you mean
WHEEEEEE!
A Thought re Huff vs Seth
Actually 'ole Seth & Cramer did the true followers of GTE a very big favor. They enabled Huff to prove his mettle in trying circumstances and the result was that Tim Huff came out proving he is a true leader. We are at war with folks who would like nothing more than to destroy GTE. In war it is always reassuring to know for sure that your leader knows what he/she is doing. I believe that IF there were any doubters about the leadership of GTE that over the last 30 days or so Tim has shown what he is made of....Eat your heart out Cramer & Seth.
Thank you Tim
Bill T
Roswell NM
Interesting Info Re Access 5 Project
Covers a great deal of info regarding high altitude platforms
http://www.access5.aero/site_content/products/Access-5-CONOPS-v2.0.pdf
Gordon...
I'm in Branchville visiting my son & daughter-in-law. We are only in for a few days....will be catching a local farm team tonite......
I don't post on RB anymore.....too many alpha hotels.....They define the term computer rage.
Best ofr luck to us this week and in the next 4 weeks....this should fly & if not I'm history.
Bill
Hi Gang
Hey, keep the faith...this bird will fly.
Just arrived in NJ for a visit......Hope to see this in the 20's by the time I get back to the desert.......